Skip to main content

Rani Therapeutics Holdings, Inc.

corporate_fare Company Profile

Rani Therapeutics Holdings, Inc.

RANI·NASDAQ·Life Sciences·CIK 0001856725

We are a clinical stage biotherapeutics company focused on developing technologies for the oral administration of biologics and drugs. Our goal is to offer a convenient alternative to injections for patients, physicians, and healthcare systems. We are advancing a portfolio of oral therapeutics using our proprietary delivery technology and are actively seeking partnerships with third-party biopharmaceutical companies to apply our technology for the oral delivery of their biologics and drugs. Our technology is a drug-agnostic oral delivery platform called the RaniPill capsule, designed to deliver various drug substances, including antibodies, proteins, peptides, and oligonucleotides. The platform has two configurations: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. We have completed three Phase 1 clinical trials using the RaniPill GO. The RaniPill HC is a high-capacity version intended to deliver drug payloads up to 200µL in liquid form with high bioavailability. We have tested the RaniPill HC preclinically with multiple therapeutics, including different antibodies and peptides. In December 2025, we initiated a Phase 1 clinical trial with RT-114, a RaniPill HC capsule containing a GLP-1/GLP-2 dual agonist (PG-102), for the treatment of obesity. We do not have any products approved for sale and have not yet generated revenue from commercial product sales.

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for RANI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for RANI spans 8-K, 10-Q, SCHEDULE 13D/A, 424B5.

Recent high-impact activity:

  • Rani Wins 180-Day Nasdaq Extension to May 10, 2027, Moves to Nasdaq Capital Market
  • Rani Q3 Loss Widens to $8.8M; $45.3M Cash Funds Operations Through 2027
  • Nasdaq Delisting Deadline and Unremediated Material Weakness Weigh on Rani Therapeutics
  • Rani Therapeutics Q2 2026: RT-114 Expansion Cohort Dosed, Cash Runway Through 2027
  • Rani's Oral Obesity Drug RT-114 Beats Injectable on Bioavailability in Phase 1a

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.63M
Net Income
-$29.67M
Diluted EPS
-$0.45
Op. Cash Flow
-$18.71M
Free Cash Flow
-$18.8M
Operating Income
-$38.31M
Cash & Equivalents
$18.62M
Total Debt
$0
Debt / Equity
0.00×
Net Margin
-18.17×
Shares Outstanding
66.14K sh
Source: 10-K · filed 2026-03-26 · accession 0001193125-26-126417

Short Interest & Short Volume

17.20 days to cover

FINRA reported short interest of 8,219,380 shares in RANI as of the October 30, 2026 settlement, a 0.8% increase from the prior period — about 17.2 days to cover at its recent average daily volume. On November 19, 2026, 70.3% of RANI volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)8,219,380 shares as of October 30, 2026
Change vs prior period▲ 0.8%
Days to cover17.20 at avg daily volume of 477,910
Daily short volume (FINRA facilities)70.3% of 284,499 shares on November 19, 2026
5-day average short volume51.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for RANI, detected from its recent SEC filings · based on capital-structure filings through 2026-05-27.

1 recent capital raise

Capital Raise Finalized · Pricing at Premium

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with R →
$0.5632 -3.00% today
52-week range · as of 2026-11-12 $0.51 – $2.15
Market cap
$78.54M
Volume
72.7K (0.1× avg)
3-mo avg 553.8K
Live data · 2026-11-20 14:49 UTC · Market open

show_chartPrice Chart

Loading chart...

feed RANI - Latest Insights

RANI
Nov 12, 2026, 4:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5252
Real-time Price: $0.5632 info
Change: +$0.038 (+7%) info
Market Cap: $78.544M info
RANI
Nov 09, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.5501
Real-time Price: $0.5632 info
Change: +$0.0131 (+2%) info
Market Cap: $78.544M info
RANI
Aug 13, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.8177
Real-time Price: $0.5632 info
Change: -$0.2545 (-31%) info
Market Cap: $78.544M info
RANI
Aug 13, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.8149
Real-time Price: $0.5632 info
Change: -$0.2517 (-31%) info
Market Cap: $78.544M info
RANI
Jul 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.679
Real-time Price: $0.5632 info
Change: -$0.1158 (-17%) info
Market Cap: $78.544M info
RANI
Jun 29, 2026, 6:54 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.7378
Real-time Price: $0.5632 info
Change: -$0.1746 (-24%) info
Market Cap: $78.544M info
RANI
May 28, 2026, 5:47 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.9601
Real-time Price: $0.5632 info
Change: -$0.3969 (-41%) info
Market Cap: $78.544M info
RANI
May 26, 2026, 8:41 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.9478
Real-time Price: $0.5632 info
Change: -$0.3846 (-41%) info
Market Cap: $78.544M info
RANI
May 26, 2026, 8:38 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $0.9478
Real-time Price: $0.5632 info
Change: -$0.3846 (-41%) info
Market Cap: $78.544M info
RANI
May 26, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.01
Real-time Price: $0.5632 info
Change: -$0.4468 (-44%) info
Market Cap: $78.544M info
RANI
May 15, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.06
Real-time Price: $0.5632 info
Change: -$0.4968 (-47%) info
Market Cap: $78.544M info
RANI
May 15, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.08
Real-time Price: $0.5632 info
Change: -$0.5168 (-48%) info
Market Cap: $78.544M info
RANI
May 15, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.08
Real-time Price: $0.5632 info
Change: -$0.5168 (-48%) info
Market Cap: $78.544M info
RANI
Mar 26, 2026, 4:43 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.12
Real-time Price: $0.5632 info
Change: -$0.5568 (-50%) info
Market Cap: $78.544M info
RANI
Mar 26, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.08
Real-time Price: $0.5632 info
Change: -$0.5169 (-48%) info
Market Cap: $78.544M info
RANI
Mar 26, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $0.5632 info
Change: -$0.4866 (-46%) info
Market Cap: $78.544M info
RANI
Jan 02, 2026, 5:28 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.36
Real-time Price: $0.5632 info
Change: -$0.7968 (-59%) info
Market Cap: $78.544M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets